Inclusion Criteria:

- Subject has a solid tumor of a type known to either over-express wild-type EGFR or to
express variant III mutant EGFR (e.g., head and neck squamous cell carcinoma, non
small cell lung cancer (NSCLC), colorectal carcinoma) or a tumor known to be EGFR
positive.

- Subject must have disease that is not amenable to surgical resection or other
approved therapeutic options with curative intent.

- Subject has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to
2.

- Subject must have measurable disease per Response Evaluation Criteria In Solid Tumors
(RECIST) version 1.1.

- Inclusion criteria for Expand Safety Cohort B - subject has histologically confirmed
supratentorial glioblastoma multiforme (GBM) .

Exclusion Criteria:

- Subject has uncontrolled metastases to the central nervous system. Subjects with
brain metastases are eligible provided they have shown clinical and radiographic
stable disease for at least 1 month after definitive therapy. Subjects with
glioblastoma multiforme (GBM) are excluded from the dose escalation portion of the
study, but may be enrolled in the expanded safety cohort.

- Subject has received anticancer therapy including chemotherapy, immunotherapy,
radiotherapy, hormonal, biologic, or any investigational therapy within a period of
21 days prior to the first dose of ABT-806.

- Subject has had any adjustments of an ongoing steroid medication during the 14 days
prior to the first dose of ABT-806.

- Subject has received a prior EGFR-directed monoclonal antibody within a period of 4
weeks prior to the first dose of ABT-806.

- Subject has unresolved clinically significant toxicities from prior anticancer
therapy, defined as any Common Terminology Criteria for Adverse Events (CTCAE) Grade
2 or higher.